Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | Patients with CLL and partial response to venetoclax-obinutuzumab

Othman Al-Sawaf • 12 Jun 2020
EHA 2020
Chronic Lymphocytic Leukemia Leukemia Antibodies Obinutuzumab Venetoclax

Othman Al-Sawaf, MD, of the University Hospital of Cologne, Cologne, Germany, highlights characteristics and outcomes of patients with chronic lymphocytic leukemia (CLL) showing partial response to venetoclax-obinutuzumab. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Othman Al-Sawaf

1:47
Treatment of Richter’s transformation: recent insights
Othman Al-Sawaf • 16 Jun 2023
1:26
The expanding landscape of next-generation BTK inhibitors in CLL
Othman Al-Sawaf • 16 Jun 2023
0:56
Fixed-duration treatment strategies for frontline and relapsed CLL
Othman Al-Sawaf • 16 Jun 2023
1:43
Six-year update from CLL14: fixed-duration venetoclax + obinutuzumab for previously untreated CLL
Othman Al-Sawaf • 16 Jun 2023

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals